Status:
COMPLETED
Double-Blind Study Determining the Efficacy of CannaXR in Decreasing UVA Premutagenic and Photoaging Markers
Lead Sponsor:
MINO Labs, LLC
Conditions:
Photoaging
Eligibility:
All Genders
22-65 years
Phase:
NA
Brief Summary
Ultraviolet light A (UVA) causes oxidization of guanine to mutagenic 8-Oxoguanine (8-OxoG) and the most frequent and best characterized mutation in mitochondrial DNA (mtDNA), a deletion of 4,977 base ...
Detailed Description
Evaluations \& Schedule: Clinical phase: The study of each subject will last 4-5 weeks, with 7 visits (Screening visit 1, Baseline visit 2, Follow up visit 3, Follow up visit 4, Follow up visit 5 an...
Eligibility Criteria
Inclusion
- Population:
- Inclusion criteria:
- Healthy subjects
- 22-65 years of age
- Fitzpatrick skin types II and III
- Exclusion criteria:
- Pregnancy
- Personal history of skin cancer
- History of abnormal photosensitivity
- Tobacco smoker
- History or being exposed to other forms of radiation (other than sunlight)
- Using any drug/medication that might alter the response of skin to UVA irradiation
- Unable to undergo skin biopsies
- History of abnormal scarring
- History of exposure to the treated areas with external beam X-ray or non-solar UV light irradiation
Exclusion
Key Trial Info
Start Date :
January 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 15 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05279495
Start Date
January 15 2023
End Date
May 15 2023
Last Update
May 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Clinical and Cosmetic Research
Aventura, Florida, United States, 33180